New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
07:21 EDTICPTIntercept price target raised to $493 from $449 at Wedbush
Wedbush raised its price target for Intercept Pharmaceuticals shares to $493 saying a new Phase 2 clinical study for OCA in alcoholic hepatitis increases the company's acquisition value. The firm reiterates an Outperform rating on the stock.
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2014
08:59 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
April 12, 2014
20:04 EDTICPTIntercept reports additional positive data from POISE trial at EASL
Subscribe for More Information
April 11, 2014
09:08 EDTICPTIntercept announces OCA preclinical study data
Subscribe for More Information
April 9, 2014
07:23 EDTICPTEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
April 8, 2014
11:03 EDTICPTPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use